Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Daxor Corporation(DXR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DXR
10/02/2026: DXR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Daxor Corporation is a medical device company focused on the BVA-100, an analyzer designed for precise blood volume measurement in heart failure and fluid management. Its primary strength lies in its unique, FDA-cleared diagnostic technology that provides objective data often missing in standard clinical care. The core investment story centers on the potential for broader hospital adoption of this precision testing to improve outcomes and reduce readmissions. However, the company faces significant competition from large medical device firms and the persistent inertia of traditional clinical methods. Suitable primarily for specialized, risk-tolerant investors, the company's path to sustainability depends on its success in scaling commercial operations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Daxor represents a high-risk, high-reward play on medical technology adoption that requires long time horizons. |
| Momentum investor | Weak fit | The stock often experiences long consolidation phases rather than rapid, news-driven price momentum. |
| Value investor | Weak fit | The lack of consistent profitability makes traditional valuation metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not provide a regular dividend income stream. |
| Low-risk investor | Weak fit | The company's status as a small-cap diagnostic developer entails high volatility and significant operational risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a small-cap firm, the stock can experience significant price swings based on limited news or sector sentiment. |
| Valuation risk | Medium / high | Without stable earnings, the company's valuation is highly speculative. |
| Competition risk (Cardiovascular monitoring) | High | Daxor must compete against global conglomerates with massive sales and distribution networks. |
| Business quality | Medium | While the technology is niche, the business model relies heavily on market adoption of a specific testing procedure. |
| Dividend income | Low / none | Investors should not expect income returns from this equity. |
| Execution risk | High | The success of the firm rests on its ability to successfully commercialize its medical device across hospitals. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -30.9% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 64.10M USD | Price to earnings Ratio 6.65 | 1Y Target Price 20 |
Price to earnings Ratio 6.65 | 1Y Target Price 20 | ||
Volume (30-day avg) 33.8K shares | Beta 0.26 | 52 Weeks Range 8.56 - 14.76 | Updated Date 10/02/2026 |
52 Weeks Range 8.56 - 14.76 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.65 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Blood Volume Diagnostics | BVA-100 analyzer sales, test kits, and associated diagnostic service fees. | The company earns revenue by selling specialized medical machines and the recurring test kits required to operate them. |
Valuation
Trailing PE 6.65 | Forward PE 64.52 | Enterprise Value 42.93M | Price to Sales(TTM) 2044.12 |
Enterprise Value 42.93M | Price to Sales(TTM) 2044.12 | ||
Enterprise Value to Revenue 8.33 | Enterprise Value to EBITDA - | Shares Outstanding 5.84M | Shares Floating 2.90M |
Shares Outstanding 5.84M | Shares Floating 2.90M | ||
Percent Insiders 49.5 | Percent Institutions 7.02 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Daxor Corporation
Exchange NASDAQ | Headquarters Oak Ridge, TN, United States | ||
IPO Launch date 1992-03-17 | Chairman, President & CEO Mr. Michael Richard Feldschuh | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.daxor.com |
Full time employees - | Website https://www.daxor.com | ||
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.